✦ LIBER ✦

Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor

✍ Scribed by Marjan de Groot; Marcel B. M. Teunissen; Jean P. Ortonne; Julien R. Lambert; Jean M. Naeyaert; Daisy I. Picavet; M. Gladys Arreaza; Jason S. Simon; Maarten Kraan; Jan D. Bos; Menno A. de Rie

Publisher: Springer-Verlag
Year: 2007
Tongue: English
Weight: 488 KB
Volume: 299
Category: Article
ISSN: 0340-3696
DOI: 10.1007/s00403-007-0764-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Δ32 Polymorphism of the chemokine recept

Δ32 Polymorphism of the chemokine receptor CCR5 in a patient with multifocal motor neuropathy

✍ Corinna Trebst; Hans Heiken; Reinhold E. Schmidt; Anja Windhagen; Martin Stangel 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Safety and tolerability of bazedoxifene

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

✍ T. J. de Villiers; A. A. Chines; S. Palacios; P. Lips; A. Z. Sawicki; A. B. Levi 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 269 KB

Efficacy and safety of infliximab in pat

Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT)

✍ Désirée van der Heijde; Ben Dijkmans; Piet Geusens; Joachim Sieper; Kimberly DeW 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 2 views

Comparing the efficacy of cyclooxygenase

Comparing the efficacy of cyclooxygenase 2–specific inhibitors in treating osteoarthritis: Appropriate trial design considerations and results of a randomized, placebo-controlled trial

✍ Allan Gibofsky; Gary W. Williams; Frank McKenna; John G. Fort 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Gabapentin in patients with the pruritus

Gabapentin in patients with the pruritus of cholestasis: A double-blind, randomized, placebo-controlled trial

✍ Nora V. Bergasa; Monnie McGee; Iona H. Ginsburg; Danielle Engler 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB 👁 2 views

Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception. The aim of this double-blind, randomized, placebo-controlled trial was to study the effect of gabapentin on the